TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.

A K Gopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.